Literature DB >> 6818542

Purification and characterization of a highly purified human factor VIII consisting of a single type of polypeptide chain.

P J Fay, S I Chavin, D Schroeder, F E Young, V J Marder.   

Abstract

Human factor VIII was purified 350,000-fold (relative to plasma) from a commercial factor VIII concentrate. The procedure used standard protein separation techniques and was performed in the absence of protease inhibitors. The product has a specific activity of 4,900 units/mg, an activity-to-antigen ratio of 75:1 (unit/unit) and no more than 0.1% von Willebrand protein. Electrophoresis of the reduced protein in a denaturing polyacrylamide gel showed a single major band of Mr 100,000. Procoagulant activity was eluted from a nondenaturing gel after electrophoresis in the region of the single major band. Thrombin converted the Mr 100,000 polypeptide to a polypeptide of Mr 75,000. The procoagulant activity was increased 10-fold by thrombin or factor Xa and was completely inhibited by activated protein C or factor VIII inhibitor plasma. This factor VIII preparation consists of a single high molecular weight polypeptide chain and has the highest specific activity thus far reported for human factor VIII.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6818542      PMCID: PMC347306          DOI: 10.1073/pnas.79.23.7200

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.

Authors:  M E Switzer; P A McKee
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

2.  High specific activity iodination of gamma-globulin with iodine-131 monochloride.

Authors:  R W HELMKAMP; R L GOODLAND; W F BALE; I L SPAR; L E MUTSCHLER
Journal:  Cancer Res       Date:  1960-11       Impact factor: 12.701

3.  Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure.

Authors:  R D LANGDELL; R H WAGNER; K M BRINKHOUS
Journal:  J Lab Clin Med       Date:  1953-04

4.  Activation of human factor X (Stuart factor) by a protease from Russell's viper venom.

Authors:  R G Di Scipio; M A Hermodson; E W Davie
Journal:  Biochemistry       Date:  1977-11-29       Impact factor: 3.162

5.  Radioimmunoassay for coagulant factor VIII-related antigen (VIII:CAg).

Authors:  H M Reisner; E S Barrow; J B Graham
Journal:  Thromb Res       Date:  1979-01       Impact factor: 3.944

Review 6.  The factor VIII complex: structure and function.

Authors:  L W Hoyer
Journal:  Blood       Date:  1981-07       Impact factor: 22.113

7.  Reactions of thrombin with human factor VIII/von Willebrande factor protein.

Authors:  M E Switzer; P A McKee
Journal:  J Biol Chem       Date:  1980-11-25       Impact factor: 5.157

8.  Analysis of factor VIII coagulant antigen in normal, thrombin-treated, and hemophilic plasma.

Authors:  M Weinstein; L Chute; D Deykin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

9.  The effect of thrombin on human factor VIII. Cleavage of the factor VIII procoagulant protein during activation.

Authors:  L W Hoyer; N C Trabold
Journal:  J Lab Clin Med       Date:  1981-01

10.  Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor.

Authors:  T S Zimmerman; O D Ratnoff; A E Powell
Journal:  J Clin Invest       Date:  1971-01       Impact factor: 14.808

View more
  11 in total

1.  Tissue-specific expression in the salivary glands of transgenic mice.

Authors:  T R Mikkelsen; J Brandt; H J Larsen; B B Larsen; K Poulsen; J Ingerslev; N Din; J P Hjorth
Journal:  Nucleic Acids Res       Date:  1992-05-11       Impact factor: 16.971

2.  YopM inhibits platelet aggregation and is necessary for virulence of Yersinia pestis in mice.

Authors:  K Y Leung; B S Reisner; S C Straley
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

3.  Production and Purification of Rabbit's Polyclonal Antibody Against Factor VIII.

Authors:  Simin Sohrabi; Azim Akbarzadeh; Dariush Norouzian; Ali Farhangi; Mehri Mortazavi; Mohammad Reza Mehrabi; Mohsen Chiani; Zahra Saffari; Soheil Ghassemi
Journal:  Indian J Clin Biochem       Date:  2011-06-08

4.  Two distinct forms of Factor VIII coagulant protein in human plasma. Cleavage by thrombin, and differences in coagulant activity and association with von Willebrand factor.

Authors:  M J Weinstein; L E Chute
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

5.  Activation of human protein C by blood coagulation factor Xa in the presence of anionic phospholipids. Enhancement by sulphated polysaccharides.

Authors:  J M Freyssinet; M L Wiesel; L Grunebaum; J M Pereillo; J Gauchy; S Schuhler; G Freund; J P Cazenave
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

Review 6.  Perioperative management of patients with von Willebrand's disease.

Authors:  C B Cameron; N Kobrinsky
Journal:  Can J Anaesth       Date:  1990-04       Impact factor: 5.063

7.  Von Willebrand protein binds to extracellular matrices independently of collagen.

Authors:  D D Wagner; M Urban-Pickering; V J Marder
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

8.  Engineering Factor Viii for Hemophilia Gene Therapy.

Authors:  Sean A Roberts; Biao Dong; Jenni A Firrman; Andrea R Moore; Nianli Sang; Weidong Xiao
Journal:  J Genet Syndr Gene Ther       Date:  2011-12-21

9.  Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.

Authors:  K M Brinkhous; H Sandberg; J B Garris; C Mattsson; M Palm; T Griggs; M S Read
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

10.  Inhibition of disulfide bonding of von Willebrand protein by monensin results in small, functionally defective multimers.

Authors:  D D Wagner; T Mayadas; M Urban-Pickering; B H Lewis; V J Marder
Journal:  J Cell Biol       Date:  1985-07       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.